Christopher Kim - 04 Mar 2025 Form 3 Insider Report for Apimeds Pharmaceuticals US, Inc. (APUS)

Role
Chairman and CMO, Director
Signature
/s/ Nelson Mullins Riley & Scarborough LLP, Attorney-in-Fact
Issuer symbol
APUS
Transactions as of
04 Mar 2025
Net transactions value
$0
Form type
3
Filing time
08 May 2025, 17:06:11 UTC
Next filing
15 May 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Kim Christopher Chairman and CMO, Director C/O APIMEDS PHARMACEUTICALS US, INC., 2 EAST BROAD STREET, 2ND FLOOR, HOPEWELL /s/ Nelson Mullins Riley & Scarborough LLP, Attorney-in-Fact 08 May 2025 0002040022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding APUS Stock option (right to buy) 04 Mar 2025 Common Stock, par value $0.01 per share 213,692 $7.33 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This stock option award is 100% vested.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney